Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors should know.
Collegium Pharmaceutical met analysts’ revenue expectations last quarter, reporting revenues of $205.4 million, up 12.9% year on year. It was a mixed quarter for the company, with full-year revenue guidance beating analysts’ expectations but a significant miss of analysts’ EPS estimates.
Is Collegium Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Collegium Pharmaceutical’s revenue to grow 3.8% year on year, slowing from the 22.7% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Collegium Pharmaceutical has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Collegium Pharmaceutical’s peers in the branded pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 55.5%, beating analysts’ expectations by 13.7%, and Supernus Pharmaceuticals reported revenues up 38.6%, topping estimates by 7.7%. Eli Lilly traded up 13.2% following the results.
Read our full analysis of Eli Lilly’s results here and Supernus Pharmaceuticals’s results here.
There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 6.5% on average over the last month. Collegium Pharmaceutical is up 8.3% during the same time and is heading into earnings with an average analyst price target of $54.17 (compared to the current share price of $35.31).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.